Arthritis, Psoriatic
Conditions
Brief summary
The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).
Detailed description
Psoriatic arthritis (PsA) is a seronegative inflammatory spondylarthritis associated with psoriasis (PsO), which can cause pain and swelling in the joints, sausage-shaped swelling of the fingers and toes (dactylitis), inflammation of the muscle- or tendon insertions at adjacent bone (enthesitis), as well as raised red patches or various other expressions of psoriasis on the skin. Guselkumab (TREMFYA) is a fully human immunoglobulin G1 lambda (IgG1) monoclonal antibody (mAb) that binds to the p19 subunit of human interleukin (IL) 23 with high specificity and affinity, blocking IL-23 binding. Binding of guselkumab to the IL-23p19 subunit blocks the subsequent binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling and subsequent activation and cytokine production. Participants with confirmed diagnosis of PsA who are starting guselkumab or any marketed interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of PsA biologic therapy per standard clinical practice will be enrolled in the main study. The aim of main study is to document the use of guselkumab and approved IL-17i therapies in routine clinical practice in patients with PsA who are starting guselkumab or an IL-17i as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy. The overall duration of the main study, including recruitment and follow-up, is expected to be about 6 years. Participants who are starting guselkumab or an IL-17i treatment per routine clinical practice in the main study, and who meet the selection criteria for both the main study and substudy, will be consecutively offered entry into the substudy (a select number) at the time of enrollment into the main study. The substudy aims to collect additional data, continuously or with increased frequency, on the impact of guselkumab or IL-17i on patient mood, physical activity, sleep disturbance, disease symptoms, and health-related quality-of-life (HRQoL). Total duration of the substudy will be approximately 26-30 weeks consisting of a pre-treatment period of up to 14 days before the first dose of guselkumab or IL-17i in the main study and a 24-week (plus \[+\] up to 4 weeks follow-up) observation period.
Interventions
DRUGGuselkumab
Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
DRUGIL-17i
Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.
Sponsors
Janssen Pharmaceutica N.V., Belgium
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
Main study: * Have a confirmed diagnosis of PsA as determined by a rheumatologist with reference to Classification criteria for Psoriatic Arthritis (CASPAR) * Start guselkumab or any approved interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy for the indication of PsA as part of standard clinical practice (according to local label, local regulations, and/or reimbursement requirements) at the time of enrollment into the observational study or within a maximum of 2 months after the initial baseline visit or after repeated baseline data collection * Sign a participation agreement/Informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements * Able to read, understand, and intend to comply with completion of all Electronic patient-reported outcome (ePRO) instruments * The treatment decision must be taken by the participating rheumatologist prior to, and independently of the participant's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations Substudy: * Must sign the substudy ICF allowing data collection in accordance with local requirements * Is scheduled to receive guselkumab or IL-17i, per routine clinical practice, in the main study * Currently using or is willing to use wearables and/or commercial applications to track their disease within the course of their normal daily activities
Exclusion criteria
Main study: * Start guselkumab or an IL-17i therapy as fifth or further line of biologic treatment * Have already taken a specific IL-17i or IL-23i treatment and are planning on re-taking that specific treatment again * Unwilling or unable to participate in long-term data collection * Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study (that is, signing of informed consent) * Currently enrolled in any interventional study or any Janssen-sponsored observational clinical study (contemporary participation into observational studies or registries not sponsored by Janssen is acceptable) Substudy: * Have an insufficient command of language to interact effectively with the smartphone application, in the opinion of the investigator at each site * Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (example, compromise the well-being) or that could prevent, limit, or confound assessment * Unwilling or unable to comply with substudy assessments
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Start and Stop Date of Guselkumab, as Applicable, For Each Participant | Up to 39 months | The start and stop date, (first and last administration date, respectively) of guselkumab, as applicable, for each participant will be collected to document treatment persistence. |
| The Start and Stop Date of Interleukin-17 Inhibitor (IL-17i), as Applicable, For Each Participant | Up to 39 months | The start and stop date (first and last administration date respectively) of IL-17i, as applicable, for each participant will be collected to document treatment persistence. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in Patient Acceptable Symptom State (PASS) | Baseline up to 39 months | The PASS measures the level of symptoms beyond which participants consider themselves well. The PASS addresses the concepts of low disease activity, partial remission in symptoms, and well-being. |
| Change from Baseline in 66 and 68 Joint Counts for Swelling and Tenderness, Respectively | Baseline up to 39 months | Change from baseline in 66 and 68 joint counts for swelling and tenderness, respectively will be reported. Joints assessed include the distal interphalangeal, proximal interphalangeal, and metacarpophalangeal joints of the hands; the wrist, elbow, shoulder, acromioclavicular, sternoclavicular, temporomandibular, hip (excluded for swelling), knee, ankle, and midtarsal joints; and the metatarsophalangeal and proximal interphalangeal joints of the feet. |
| Change from Baseline in Assessment of Enthesitis using Leeds Enthesitis Index (LEI) | Baseline up to 39 months | The presence and a score of enthesitis will be documented using the LEI to evaluate the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: the lateral epicondyles (left and right), medial femoral condyles (left and right), and Achilles tendon insertions (left and right). |
| Change from Baseline in Nail Involvement | Baseline up to 39 months | Nail involvement will be documented by recording the total number of nails of the hands and feet (that is, 0 to 20) with psoriatic nail changes. |
| Change from Baseline in Body Surface Area (BSA) Psoriasis (PSO) Skin Involvement | Baseline up to 39 months | The BSA score indicates the surface area of the participant's body effected by psoriasis. |
| Change from Baseline in C-reactive Protein (CRP) | Baseline up to 39 months | Change from baseline in CRP will be reported. |
| Change from Baseline in Minimal Disease Activity (MDA)/ Very Low Disease Activity (VLDA) | Baseline up to 39 months | Change from Baseline in MDA/VLDA will be reported. |
| Change from Baseline in Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA/DAPSA) | Baseline up to 39 months | DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively. |
| Response as a Measure of Clinical Improvement in cDAPSA/DAPSA | Up to 39 months | Response is defined as a clinical improvement in cDAPSA/DAPSA. DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively. |
| Start and Stop Dates of All Treatments and the Sequence of Treatment Lines | Up to 39 months | Start and stop dates of all treatments and the sequence of treatment lines will be reported. |
| Percentage of Participants with Adverse Events (AEs) | Up to 39 months | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
| BSA PSO Skin Involvement | Up to 39 months | The BSA score indicates the surface area of the participant's body affected by psoriasis. |
| Rheumatic Disease Comorbidity Index | Up to 39 months | Number of comorbid medical conditions of the study participants for the Rheumatic Disease Comorbidity Index will be reported. |
| Change from Baseline in Fibromyalgia Rapid Screening Tool (FiRST) | Baseline up to 6 months | FiRST will be used to help determine whether participants have chronic widespread pain or fibromyalgia syndrome at entry into the study. The FiRST is a validated questionnaire consisting of a combination of 6 items that can detect chronic widespread pain. |
| Change from Baseline in European Quality of Life (EuroQoL) 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L) | Baseline up to 39 months | The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems, where Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems and Level 5: extreme problems. |
| Change from Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline up to 39 months | The functional status of the participants will be assessed by the HAQ-DI. This 20-question self-administered instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area. |
| Change from Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12) | Baseline up to 39 months | PsAID-12 is a validated, self-administered questionnaire that assesses the impact of PsA on participants' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly). |
| Change from Baseline in Patient Global Disease Activity Visual Analog Scale (VAS) Scores | Baseline up to 39 months | The Patient Global Disease Activity VAS is a self-administered assessment with scores ranging from "very well" (0 mm) to "very poor" (100 mm) that assesses disease activity over the past week. |
| Change from Baseline in Pain VAS Score | Baseline up to 39 months | The pain VAS is a self-administered assessment of average pain during the past week. The scale ranges from "no pain" (0 mm) to "the worst possible pain" (100 mm). |
| Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | Baseline up to 39 months | BASDAI consists of a 1 through 10 scale (1 being no problem and 10 being the worst problem) which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity. |
| Change from Baseline in Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP) | Baseline up to 39 months | The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the CRP value. |
| Change from Baseline in Dermatology Life Quality Index (DLQI) | Baseline up to 39 months | The DLQI is a dermatology-specific, validated, 10-question quality of life instrument used to measure the impact of skin disease on the quality of life of an affected person. Each question will address how much the participant's skin problem has affected their life and is scored as: 3 = very much, 2 = a lot, 1 = a little, 0 = not at all, or not relevant. |
| Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI: PsA) | Baseline up to 39 months | The WPAI: PsA is a validated, self-administered questionnaire that assesses work and activity impairment during the past 7 days. The WPAI: PsA produces 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. The WPAI: PsA outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes. |
| Change from Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) | Baseline up to 39 months | TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and side effects of the medication. |
| Change from Baseline in Rheumatologist's Global Assessment of Disease Activity-Psoriatic Arthritis (PGA-PsA) | Baseline up to 39 months | The PGA-PsA will be documented using a Visual Analogue Scale (VAS) that ranges from "no PsA activity" (0 Millimeter \[mm\]) to "extremely active PsA" (100 mm). |
| Number of Participants Switching or Stopping Treatment | Up to 39 months | Number of Participants switching or stopping treatment (including reasons for discontinuation) will be reported. |
| Change from Baseline in Assessment of Dactylitis | Baseline up to 39 months | The presence of and total number of digits of the hands and feet (that is, 0 to 20) with dactylitis will be documented. |
Countries
Argentina, Australia, Austria, Belgium, Canada, Colombia, France, Germany, Greece, Italy, Japan, Mexico, Netherlands, Russia, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Contacts
STUDY_DIRECTORJanssen Pharmaceutica N.V., Belgium Clinical Trial
Janssen Pharmaceutica N.V., Belgium
Outcome results
None listed